Guy Yachin


Guy Yachin is the CEO and Executive Chairman of Xerient, a drug development company focused on enhancing radiation therapy. He has served as CEO of Serpin Pharma, a Virginia based immunotherapy company, and prior of Nasvax, a company focused on the development of improved immunotherapeutics and vaccines. As the CEO he has led Vessl Ltd., a cell therapy company focused on blood vessels disorders, through clinical studies in the U.S. and Israel, financial rounds, and a keystone strategic agreement with Teva Pharmaceuticals Industries Ltd. Prior to that he was CEO and founder of Chiasma Inc. (Nasdaq:CHMA), a biotechnology company focused on the oral delivery of macromolecule drugs, where he built the company’s presence in Israel and the U.S., concluded numerous financial rounds, and guided the company’s strategy and operation for over six years. Earlier he was CEO of Naiot Technological Center Ltd., and provided seed funding and guidance to more than a dozen biomedical startups such as Remon Medical (acquired by Boston Scientific), Enzymotec (Nasdaq:ENZY). He holds a BSc. in Industrial Engineering and Management and an MBA from the Technion – Israel Institute of Technology.

Nitin Kaushal


Mr. Kaushal is a Managing Director in the Deals practice at PwC Canada. Nitin has more than 25 years experience in the financial investing, life sciences, consumer health care, health care services and medical device industries. His experience includes board of directorships with pharmaceutical and health care companies. He has also held senior roles in investment banking, venture capital and consulting firms. Nitin has performed over 50 merger, acquisition, strategic advisory, and licensing assignments. He has been an advisor to many of the leading global pharma companies and has participated in capital market transactions raising in excess of $2Bn.

Nancy Retzlaff


Nancy Retzlaff is a seasoned biopharmaceutical executive with over 20 years of experience. She began her career in the pharmaceutical industry with Bayer Healthcare in Canada and has since has since held commercial leadership positions of increasing responsibility at Bayer US, Schering-Plough and Pfizer. She has also held senior level positions at two start-up biopharma organizations. Nancy brings a track record of leading successful product launches globally as well as in the US, Europe, Japan & Canada, and has led a number of high profile brands including Cipro, Remicade, Lyrica, Aricept and Eliquis. She has broad therapeutic expertise in pain, immunology, neurosciences, infectious diseases and cardiology. Her deep commercial experience spans early commercial development through to life cycle management. Nancy has also served as an advisor to global pharma as well as early start-up companies.

Soren Mogelsvang, PhD

Director, President and CEO

Dr. Mogelsvang is a biotech executive and entrepreneur with over 15 years of experience. He is the co-founder of several biotech companies and brings a track record in building and leading privately funded and publicly traded companies. Recent positions he has held include President and CEO of Peak Pharmaceuticals, which he built from concept to a profitable veterinary health company; Co-founder and VP of R&D at Serpin Pharma, a clinical stage biotech company; Co-founder and Head of R&D at Caerus Discovery, an immunology company launched with support from BioWa – Kyowa Hakko Kirin and ImmunoCellular Therapeutics; Head of Cell Biology at ATCC; and Director of Laboratory and Production at Affinity BioReagents. Soren has PhD in Biochemistry (Cambridge, UK), and an MSc in Plant Molecular Biology (University of Copenhagen, Denmark).